| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f47c750954e13a1ed0be96c1bf1c51c7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43e13815e78955c37ca84ad1f9a92534
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_213eb17745e786c60032aa2561b76cd6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d2d919ac2682bba3b1769e93a225a559
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d4458f724321655634a48591e558b686 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-91142
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-98
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-10 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5047 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0787 |
| filingDate |
2010-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2013-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c181b872968b6ef38340e23dbc5028d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e7d61259328f1d2ee61c37721201df27
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_03cc22003ee41d3e19776676de3fe655
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_258a267dabcb4a32a844507c1ceed4da |
| publicationDate |
2013-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8580488-B2 |
| titleOfInvention |
Cell culture model for acquired chemoresistance of chronic myelogenous leukemia and related methods for identifying agents to overcome resistance |
| abstract |
A method of generating a chronic myelogenic leukemia (CML) acquired chemoresistant culture model is provided. Such a method may comprise providing a naïve blast crisis CML cell line; administering/contacting the cell line with a mutation-inducing dose of imatinib; maintaining a culture of the treated cell line for a period of time until the treated cell line relapses and repopulates the culture; and determining the repopulated cell culture is a CML acquired chemoresistant cell line by detecting a BCR-ABL mutation, wherein the acquired chemoresistance is achieved by a BCR-ABL mutation. |
| priorityDate |
2007-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |